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Abstract
Peripheral lung lesions treated with a single fraction of stereotactic ablative body
radiotherapy (SABR) utilizing volumetric modulated arc therapy (VMAT) delivery and
flattening filter‐free (FFF) beams represent a potentially high‐risk scenario for clini-
cally significant dose blurring effects due to interplay between the respiratory
motion of the lesion and dynamic multi‐leaf collimators (MLCs). The aim of this
study was to determine an efficient means of developing low‐modulation VMAT
plans in the Eclipse treatment planning system (v15.5, Varian Medical Systems, Palo
Alto, USA) in order to minimize this risk, while maintaining dosimetric quality. The
study involved 19 patients where an internal target volume (ITV) was contoured to
encompass the entire range of tumor motion, and a planning target volume (PTV)
created using a 5‐mm isotropic expansion of this contour. Each patient had seven
plan variations created, with each rescaled to achieve the clinical planning goal for
PTV coverage. All plan variations used the same field arrangement, and consisted of
one dynamic conformal arc therapy (DCAT) plan, and six VMAT plans with varying
degrees of modulation restriction, achieved through utilizing different combinations
of the aperture shape controller (ASC) in the calculation parameters, and monitor
unit (MU) objective during optimization. The dosimetric quality was assessed based
on RTOG conformity indices (CI100/CI50), as well as adherence to dose–volume
metrics used clinically at our institution. Plan complexity was assessed based on the
modulation factor (MU/cGy) and the field edge metric. While VMAT plans with the
least modulation restriction achieved the best dosimetry, it was found that there
was no clinically significant trade‐off in terms of dose to organs at risk and confor-
mity by reducing complexity. Furthermore, it was found that utilizing the ASC and
MU objective could reduce plan complexity to near‐DCAT levels with improved
dosimetry, which may be sufficiently robust to overcome the interplay effect.
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1 | INTRODUCTION
Volumetric modulated arc therapy (VMAT) provides modulation via
continuous multileaf collimator (MLC) motion and dose rate modula-
tion during gantry rotation.1,2 This complex delivery is derived
through inverse planning, which provides the ability to tune the
treatment plan dosimetry. Although modulated delivery is best uti-
lized for complex target‐organ at risk geometry, VMAT is used for a
range of treatment sites throughout the body.3–5 As an example,
peripheral lung stereotactic ablative body radiotherapy (SABR) vol-
umes are typically not complex in shape and in many cases are not
proximal to serial organs at risk, so there is little indication to create
modulated plans. The main benefits of using VMAT in this context
are highly efficient delivery and in general a more efficient planning
process compared with 3D conformal treatments which require man-
ual tuning of beam weights. The main benefits of VMAT in lung
SABR thus may be the use of variable dose rate and gantry speeds
that are produced by the optimizer, rather than complex aperture
shapes.
When delivering modulated treatments to moving targets, there
is a potential risk of interplay between tumor and MLC motion.
Extensive research has shown this has limited impact in conventional
fractionation due to the effects “blurring out” over the course of
treatment; however, when using SABR which is typically delivered in
1–5 fractions this fractionation benefit may not hold.6,7 Interplay‐in-
duced dose discrepancies increase with decreasing number of
breathing cycles completed by the patient during the treatment
beam‐on time.6–8 Reducing aperture complexity,7,8 increasing the
number of beams and fractions,6,8 reducing the dose rate,8,9 and
treating with higher dose per fraction have been shown to reduce
the risk of clinically significant interplay effects.6,8,10 Furthermore,
some studies also suggest that the risk of clinically significant inter-
play effects increase with tumor motion amplitude.9,11 Limited data
exists, however, for flattening filter‐free (FFF) dose rates and single
fractions >18 Gy.6–8,10 This means that single fraction lung cases
treated with FFF beams represent a potentially high‐risk scenario,
and that reductions in aperture complexity are highly desirable to
retain the benefits of VMAT while limiting the dosimetric impact.
The aim of this planning study was to determine an efficient means
of developing low‐modulation VMAT plans in order to minimize the
risk of interplay for single fraction lung SABR with high dose‐rate
FFF beams.
2 | MATERIALS AND METHODS
We selected 19 sequential lung SABR patients treated with a single
28 Gy fraction at our institution. Each patient was simulated using a
4DCT, with an internal target volume (ITV) contoured on the average
intensity projection (AIP) while referencing the individual phases of
the 4DCT and the maximum intensity projection (MIP). The AIP was
used for contouring, planning, and dose computation. ITV volumes
ranged from 0.3 to 20.3 cm3 (average 4.8 cm3), and the planning
target volume (PTV) was created by adding an isotropic 5 mm mar-
gin to the ITV. All treatment planning was performed in the Eclipse
treatment planning system (v15.5, Varian Medical Systems, Palo Alto,
USA) using the photon optimizer (v15.5). Dose calculation was per-
formed using the AcurosXB algorithm reporting dose to medium
(v15.5).
Treatment plans using three arcs were created for each patient.
The selected beam arrangement ensured that both dosimetrically
acceptable dynamic conformal arc therapy (DCAT) and VMAT plans
were produced. Two coplanar 210° arcs on the ipsilateral side (typi-
cal of VMAT), plus a 60° anterior noncoplanar arc delivered at couch
90° (typical of DCAT at our institution) were used, with the isocen-
ter placed at the center of the target. Each plan used unique collima-
tor angles for each beam, ranging from ±5°to 45°. In each patient, all
plan types used identical jaw settings. All plans were rescaled to
match the coverage requirement of 99% of the PTV covered by pre-
scription dose (PTV D99% = 100%). All plans were developed using
the clinical 6 MV FFF beam model allowing up to 1400 MU/min, for
a Varian TrueBeam (TB) or TrueBeam STx (TBSTx), with the Millen-
nium 120 MLC (5 mm central leaves) or Millennium HD 120 MLC
(2.5 mm central leaves), respectively.
The optimization parameters tested to reduce modulation com-
plexity were the aperture shape controller (ASC) and the monitor
unit (MU) objective. The ASC defines aperture complexity by con-
straining the difference in allowable positions for adjacent leaves.
There are six settings ranging from “None” (no constraints) to “Very
High” (maximum constraint), which must be applied prior to entering
the optimizer. The MU objective can be applied in the optimization
environment and allows the user to define a minimum and maximum
target MU for the plan. A penalty is applied to the optimizer cost
function if the planned MU are not within the defined range, and
this penalty is weighted by the “strength” assigned to the MU objec-
tive (a value between 0 and 100). This allows the MU objective to
be used as a tool for creating efficient plan delivery, and therefore,
its success was measured based on the level of reduction to plan
complexity, rather than ability to achieve the a specific target MU.
The application of these parameters was compared to a previously
established method of modulation reduction known as “hybrid
VMAT” (hVMAT).
Each plan variation was created from an initial VMAT plan devel-
oped following standard institutional procedure in order to establish
the appropriate optimization objectives, to be used in all subsequent
VMAT plans. Jaws were set by first fitting the MLC to the PTV with
a 3 mm margin, and then using the Varian recommended jaw set-
tings which positions them 2 mm from the most extended leaf.
These plans used the institutional default ASC setting of “Moderate.”
Other ASC settings were applied by copying this plan, changing the
setting, and reoptimizing from new with all other objectives and set-
tings held constant, and no user interaction. The DCAT plan was cre-
ated by copying the first VMAT plan, replacing the MLC with
conformal MLCs, and recalculating the dose using the VMAT field
weights. In order to apply the MU objective, a two stage optimiza-
tion was performed. That is, a VMAT plan (with the desired ASC
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setting) was used as the starting point, before reoptimizing with the
desired MU objective applied, selecting the “continue optimization
using current plan as base dose” option (which only proceeds
through multiresolution levels 3 and 4 of optimization) with no fur-
ther user interaction.. The hVMAT plan was created using the DCAT
plan as the starting point, before reoptimizing, and once again select-
ing the “continue optimization” option with no further user interac-
tion. This has a similar effect to applying the MU objective because
the DCAT plan used as a starting point has significantly less MU
than a standard VMAT. The hVMAT method for modulation suppres-
sion, however, requires both an initial VMAT plan (to provide the
optimization objectives), and a DCAT plan (to provide the target
MU), and is therefore a less efficient process than utilizing the MU
objective.
Analysis was performed on a total of 19 sets of plans — 9 using
the TBSTx model and 10 using the TB model. The optimum MU
objective settings (maximum MU = 40% of original, strength = 80)
were determined by trialing a broad combination of settings on the
TBSTx patients (see Table A1, Appendix A). Note that the input max-
imum MU is determined as a fraction (%) of the original MU. These
were the most penalizing settings trialed, and were selected to
assess the maximum plan quality detriment as a result of modulation
reduction. The MU objective was applied in combination with two
ASC settings (“Moderate” and “Very High”). The DCAT and ASC =
“None” VMAT plans were included for comparison to the least and
most modulated plans, respectively, and the ASC = “None” plan was
used as the benchmark case for dosimetric comparison. All plan
types were renormalized to achieve the target coverage goal of PTV
D99% = 100%.
Target doses were evaluated using the ITV D2% (as normaliza-
tion was performed using coverage). The dose conformity was
assessed using the RTOG 100% and 50% conformity indices (CI100
and CI50, respectively). The lung V5Gy, V20Gy, chest wall D30cc,
chest wall D0.5cc, spinal canal D0.5cc, esophagus, D0.5cc and skin
D0.5cc were also measured, and compared to the dose‐volume limits
used in a recent clinical trial.12 Plan complexity/robustness was eval-
uated using the modulation factor (MF) defined as the monitor units
per cGy (MU/cGy) and the edge metric (EM). The EM utilized was
based on the aperture complexity metric described in reference,13
applying the recommended weight of zero to the leaf ends when cal-
culating the aperture perimeter. A lower EM means reduced com-
plexity, but is not strictly a measure of aperture openness. All
dosimetric and plan complexity metrics were extracted using the
Eclipse Scripting Application Programming Interface (API).
TAB L E 1 Average (±1SD) for each tested outcome across all plan types.
Metric Planning goal
VMAT noASC
Avg (±1SD)
VMAT_mod
Avg (±1SD)
VMAT_Vhigh
Avg (±1SD)
DCAT
Avg (±1SD)
Mod_40_80
Avg (±1SD)
Vhigh_40_80
Avg (±1SD)
hVMAT
Avg (±1SD)
ITV D2% (Gy) >35
<40
35.74
±1.27
35.73
±1.15
35.79
±1.15
34.63 ± 1.36* 34.94
±1.03*
35.42
±1.32
35.04 ± 1.03*
RTOG
CI100
<1.2‐1.3 1.12
±0.06
1.12
±0.06
1.13
±0.06
1.67
±0.28*
1.14
±0.13
1.28
±0.17*
1.26
±0.13*
RTOG
CI50
ALARA (<~6) 4.97
±0.78
5.05
±0.75
5.19
±0.78
7.61
±1.45*
5.71
±1.4*
6.52
±1.36*
6.50
±1.4*
Lungs
V5Gy (%)
<60 7.30
±4.1
7.41
±4.13
7.52
±4.15
8.66
±4.55
7.90
±4.42
8.32
±4.14
8.27
±4.42
Lungs
V20Gy (%)
<20 0.92
±0.61
0.94
±0.63
0.96
±0.64
1.38
±0.88
1.05
±0.76
1.16
±0.66
1.18
±0.76
ChestWall D30cc (Gy) <30 7.94
±3.54
8.00
±3.63
7.98
±3.61
9.80
±4.67
8.31
±3.96
8.69
±3.69
8.83
±3.96
ChestWall D0.5cc (Gy) <28 22.38
±9.13
22.30
±9.23
22.40
±9.21
25.47 ± 10.05 21.97
±8.78
23.04
±9.05
22.91 ± 8.78
SpinalCanal D0.5cc (Gy) <12 2.59
±1.08
2.74
±1.23
2.84
±1.22
2.92
±1.13
2.80
±1.07
2.73
±1.12
2.73
±1.07
Esophagus D0.5cc (Gy)a <15.4 2.70
±1.51
2.80
±1.39
2.83
±1.49
2.82
±1.43
2.56
±1.27
2.62
±1.41
2.62
±1.27
Skin
D0.5cc (Gy)
<24 8.46
±2.69
8.26
±2.75
8.38
±2.6
10.10
±3.5
8.46
±3.23
8.87
±2.72
9.36
±3.23
MF
(MU/cGy)
NA 2.97
±0.39*,Δ
2.85
±0.39*,Δ
2.69
±0.37*,Δ
1.68
±0.15*
2.11
±0.22*,Δ
1.96
±0.20*
1.87
±0.20*
EM NA 0.21
±0.04Δ
0.18
±0.03*,Δ
0.15
±0.03*,Δ
0.06
±0.01*
0.10
±0.02*,Δ
0.07
±0.02*
0.08
±0.02*
Note: that this data is averaged across both beam models. A statistically significant difference to the VMAT_noASC result is indicated by an asterisk (*).
For the robustness metrics, a statistically significant difference to the DCAT result is shown by a delta (Δ).
aOnly 13 cases had the esophagus contoured.
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The average and standard deviation of each endpoint were
determined for each plan type. Furthermore, the average difference
of each metric from the benchmark plan (VMAT_noASC) was deter-
mined for each plan type, and a paired Student’s t‐test was per-
formed to determine the statistical significance of this difference.
Additionally, the robustness metrics (EM and MF) for each plan type
were compared to the DCAT plan using a paired Student's t‐test.
The analysis was performed grouping both the TB and TBSTx data
together; however, an assessment of the difference between the
two models was also performed.
3 | RESULTS
Table 1 presents the mean (±1SD) outcome for each metric along-
side the clinical planning goal, for each plan type. Each plan type
was compared with the benchmark plan (VMAT_noASC) via a paired
Student’s t‐test (P < 0.05). The ITV D2% was lower than the bench-
mark case for the DCAT, MU objective, and hVMAT plans, with the
maximum difference occurring in the DCAT plans. Similarly, the same
four test plans had larger conformity indices, while the VMAT plans
utilizing different ASC settings alone did not. On average, OAR
dose–volume metrics in the test plans were higher than for the
benchmark plan, but none of these differences were statistically sig-
nificant. For every plan type, the EM and MF were significantly
lower than the benchmark case (with the exception of the MF for
the VMAT with “Moderate” ASC).
Overall, there were no data to suggest a significant dosimetric
difference between the TB and TBSTx model; however, there were
some noteworthy exceptions. The skin D0.5cc using the TBSTx
model was systematically lower than the TB model for all plan types,
as depicted in Fig. 1(a). This is likely attributed to the TB patients
F I G . 1 . (a) Skin D0.5cc for each plan type and beam model. The
skin dose for the TB model is systematically higher for all plan types.
(b) Edge metric (EM) for each plan type and beam model. The EM
for the TBSTx model is systematically higher than for the TB model,
but this difference decreases as the EM decreases. (c) Modulation
factor for each plan type and beam model. There is negligible
difference in modulation factors between the two models in each
plan type.
TAB L E 2 Comparison of average EM for each beam model by plan
type.
Plan type TB EM Avg (±1SD) TBSTx EM Avg (±1SD)
VMAT_noASC 0.18 ± 0.02 0.25 ± 0.03
VMAT_mod 0.16 ± 0.02 0.20 ± 0.03
VMAT_Vhigh 0.14 ± 0.02 0.17 ± 0.04
DCAT 0.06 ± 0.01 0.07 ± 0.02
Mod_40_80 0.10 ± 0.02 0.10 ± 0.03
Vhigh_40_80 0.07 ± 0.01 0.08 ± 0.02
hVMAT 0.07 ± 0.01 0.08 ± 0.02
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having more peripheral lesions, closer to the Skin contour, since the
data did not suggest that the TB plans were more complex/modu-
lated overall. Rather, the TBSTx EM was systematically higher than
the TB model [Fig. 1(b)], in particular for the more modulated plan
types. This was expected since the TBSTx plans use a greater num-
ber of leaf pairs to define each aperture, and thus introduce more
leaf edges to the EM calculation. Despite this, the mean EMs for the
DCAT, MU objective, and hVMAT plans are comparable for both
models (see Table 2).
Due to the open apertures, DCAT is the most robust to tumor
motion of the plans investigated in this study, but the data in Table 1
shows that DCAT is generally dosimetrically inferior to VMAT plan
types. The robustness metrics for the MU objective and hVMAT
plans, however, were comparable to that of DCAT, as depicted in
Figs. 1(b) and 1(c). The statistical testing confirmed that both the
hVMAT plan and MU objective plan with “Very High” ASC showed
no significant difference to DCAT (with the MU objective plus
“Moderate” ASC only slightly different) in the robustness metrics.
4 | DISCUSSION
The VMAT with ASC set to “None” plan type was chosen as the
benchmark to illustrate the maximum achievable dosimetric plan
quality, allowing the optimizer the most modulation. The results sug-
gest that all plans tested have significantly less modulation than
these unconstrained VMAT plans, and there is little dosimetric trade‐
off in terms of OAR doses. When it comes to target dose and con-
formity, however, there is some compromise for penalizing modula-
tion (see Fig. 2). All DCAT, MU objective and hVMAT plans showed
deviations from the benchmark plan in the ITV D2%, CI100, and
CI50 quality metrics; however, the absolute outcomes of these met-
rics are clinically acceptable in all VMAT plans (Table 1).Depending
on the patient specific tumor to OAR geometry, this dosimetric trade
off may not be appropriate and other options to reduce susceptibil-
ity to interplay effects may need to be taken.
While the EM is strictly speaking a measure of aperture irregular-
ity, it can be used as a measure of VMAT aperture openness by
comparison to the DCAT result (Table 1). In order for two plans to
have the similar EM they must have a similar ratio of open to par-
tially blocked control points when MU weight is considered. Since
DCAT plans have only fully open apertures, a VMAT plan with a
comparable EM must have negligible partially blocked, irregular aper-
tures. This conclusion is consistent with the results of measurement‐
based interplay studies in the literature.9,11 In the context of the
small fields used in SABR, if the total MU (or MF) for both plans are
also similar, then they must have similar openness. In this way, we
can be confident that the EM and MF are useful as a proxy for aper-
ture openness. The use of the MU objective as described (maximum
MU = 40% of original, strength = 80) in combination with the “Very
High” ASC may therefore be appropriate for single fraction lung
SABR treatments using FFF beams at high repetition rate, as the
apertures may be sufficiently open to increase robustness to the
interplay effect.
F I G . 2 . Example isodose distributions at the isocenter (internal target volume in red, planning target volume in cyan) for each plan type for
the same patient.
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5 | CONCLUSION
We have demonstrated significant reductions in modulation com-
plexity through use of aperture shape controller and monitor unit
restriction for lung SABR VMAT plans. These reductions were
achieved with minimal dosimetric penalty, and may increase robust-
ness to respiratory motion interplay effects in single fraction SABR
with high dose rates observed with FFF beams.
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APPENDIX A
See Table A1.
TAB L E A1 Combination of metrics trailed on first 10 TBSTx
patients.
Plan type ASC
MU objective
Max MU Strength
DCAT NA NA NA
VMAT None, moderate, high, very high NA NA
hVMAT Moderate, high, very high NA NA
VMAT with Moderate, high, very high 40% 80
MU objective Moderate, high, very high 60% 95
Moderate, high, very high 70% 100
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